Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Pergolizzi

Pain Medicine Naples, FL Medical Doctor

NPI 1922198068 CMS profile 223423

868 106Th Ave N, Naples, FL 34108

Open in the dashboard

General payments

$332,662

307 records reported · program years 2019–2025

Research payments

$5,200

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,734,060 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Joseph Pergolizzi of Naples, FL is reported in the CMS Open Payments database as having received $332,662 across 307 general payments and $5,200 in research payments paid to them. Separately, studies naming them as principal investigator received $1,734,060 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $22,638 22
2024 General $72,950 38
2023 General $32,937 26
2022 General $18,787 19
2021 General $10,868 6
2020 General $28,268 32
2019 General $146,214 164
2019 Research $5,200 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Pergolizzi
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Joseph Pergolizzi were reported at $22,638. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Joseph Pergolizzi Pain Medicine median Middle half National median
2019 $146,214 $498 $126–$1,682 $163
2020 $28,268 $284 $80–$910 $114
2021 $10,868 $399 $112–$1,219 $132
2022 $18,787 $455 $137–$1,484 $149
2023 $32,937 $484 $128–$1,495 $160
2024 $72,950 $498 $131–$1,540 $164
2025 $22,638 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $91,453 106 payments
  2. Biodelivery Sciences International, Inc. $64,254 87 payments
  3. Scilex Pharmaceuticals Inc. $41,072 35 payments
  4. Bausch Health US, LLC $40,460 2 payments
  5. Daiichi Sankyo Inc. $23,250 18 payments
  6. US WorldMeds, LLC $11,837 14 payments
  7. Janssen Research & Development, LLC $9,014 7 payments
  8. Teva Pharmaceuticals USA, Inc. $8,550 1 payment
  9. Vertex Pharmaceuticals Incorporated $7,673 6 payments
  10. Bayer Healthcare LLC $5,750 2 payments
  11. Other $29,349 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $92,553 18 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $84,398 30 payments
  3. Honoraria $53,130 16 payments
  4. Travel and Lodging $39,062 134 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $36,720 6 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $20,700 7 payments
  7. Food and Beverage $6,099 96 payments
Products named General payments · program years 2019–2025
  1. RELISTOR $83,180 97 payments
  2. BELBUCA Addiction Therapy $57,970 79 payments
  3. APLENZIN $40,460 2 payments
  4. ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH $24,018 15 payments
  5. Morphabond ER $23,250 18 payments
  6. LUCEMYRA $18,784 24 payments
  7. ZTLido $17,055 20 payments
  8. Lucemyra/Lofexidine $11,337 13 payments
  9. JOURNAVX $7,673 6 payments
  10. BELBUCA Chronic Pain $6,272 7 payments
  11. Other $9,652 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Ge Healthcare $5,200 1 payment

Records

308 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record